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Regulated  Expression  and  Function of CD122 
(Interleukin-2/Interleukin-l5R-~) During  Lymphoid  Development 
By Tannishtha Reya, Julia A. Yang-Snyder, Ellen V. Rothenberg,  and  Simon R. Carding 
TO determine whether signaling  via CD122 (interleukin-2 [IL- 
21/IL-15 receptor p-chain) plays a role in regulating the 
expansion and differentiation of lymphocyte precursors, we 
have characterized its expression and evaluated its ability 
to influence the activity of developing lymphoid cells. A sig- 
nificant fraction of Scal'Lin- hematopoietic stem cells in 
day 12 fetal liver were found to  be CD122+. CD122-mRNA+ 
and IL-2-mRNA' cells were also localized in embryo sec- 
tions within pharyngeal blood vessels adjacent to and sur- 
rounding the thymic analgen. This distribution is  consistent 
with  the migration of CD122+ progenitor cells from  the liver 
to  the developing thymus where a majority of Scal' intra- 
TEM CELLS undergo a program of proliferation and 
differentiation  in  anatomically distinct sites to give rise 
to functionally competent B and T cells.  The stages  through 
which developing B and T cells pass, as distinguished by 
the differential expression of a variety of genes and cell 
surface glycoprotein antigens,  have been  well character- 
ized.l-3 However,  we still know very little about the nature 
of the mechanisms that promote  or  regulate a cell's transition 
between  these  stages. Recently,  several  lines of experimental 
evidence  have suggested  that in addition to stromal cell  con- 
tact the ability to respond to certain cytokines may be re- 
quired  for maintaining the viability and promoting  the expan- 
sion  and/or  differentiation  of B- and T-cell  progenitor 
p0pu1ations.l.~  In particular,  a  number of studies  suggest that 
the interleukin-2 (IL-2)/IL-2R signaling pathway may play 
a  role  in promoting  lymphopoiesis. 
The  expression of individual chains of the IL-2 receptor 
complex  immature B5." and T cells4.'.* in  hematopoietic  tis- 
sues of both humans  and mice  is  consistent with  the require- 
ment for a  functional  IL-2R during  lymphopoiesis.  The 
disruption  of  IL-2R function by the administration  of anti- 
IL-2R antibodies to intact animals,' by creating nonfunc- 
tional  IL-2Rs  in  transgenic  mice'" or, as  a  result of the  muta- 
tions in the y-chain of the IL-2R seen in human severe 
combined immunodeficiency disorder (X-SCID) patients' I 
also  suggest that an  intact  and functional  IL-2R may play a 
role in the development of T-cell-precursor populations. 
However, interpretation of the results of these and other 
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thymic T-cell progenitors were CD122+. Analysis of CD122 
expression in  the day 12 fetal liver revealed that  the majority 
of B220'  cells were CD122+. Furthermore, CD122  expression 
was restricted to  the earliest B220+ cells  (CD43'CD24-; pre- 
pro B cells; fraction A)  that proliferate vigorously to IL-2 in 
the absence  of any stromal cells, but .not to IL-15. Consistent 
with a role for the IL-2/lL-2R pathway  in lymphocyte devel- 
opment is the progressive loss of B cells  seen in IL-2-defi- 
cient mice. Together, these observations suggest that CD122 
plays a role in regulating normal lymphocyte development 
in vivo. 
0 1996 by The  American  Society of Hematology. 
studies of IL-2  and  lymphopoiesis is made difficult in view 
of the recent findings that the y-chain is a component of 
other cytokine receptors'*." and, that both the P-(CD122) 
and  the  y-chain  can interact  with the newly  described cyto- 
kine, IL-15.14 Thus,  ligands  other than IL-2  may  be  able  to 
influence the  development of lymphoid  cell progenitors  that 
express individual chains of the IL-2R complex. Although 
only limited  studies  of  IL- 15 have  been  reported to  date, the 
production of this cytokine by bone marrow (BM) stromal 
cells  and epithelial cell lines" implies  that it may be available 
for utilization by immature B-and T-cell populations that 
develop in the BM and  thymus, respectively. 
To  better address  the role  cytokines play during  lymphoid 
development, we have analyzed hematopoietic stem cells 
and B- and T-cell  precursors for  expression of CD122,  the 
signaling component of the  IL-2  and IL-15  receptor. More- 
over, we have also determined whether signaling through 
this  receptor  influences  hematopoietic  precursor cell activity. 
Finally, we have  analyzed  IL-2-deficient  mice to determine 
if they display any hematopoietic defects in the absence of 
one of the  known  ligands for  IL-2RP. 
MATERIALS AND METHODS 
Animals. Adult (6 to 8 weeks of age) C57BL.6 mice (Jackson 
Laboratories, Bar Harbor, ME) were bred and maintained by the 
University of Pennsylvania animal facilities. Fetal tissues were ob- 
tained from time-mated mice  with the day of detection of a vaginal 
plug designated day 0. Adult C13-SCID mice (6 to 8 weeks of age) 
were  provided by  Dr John Cebra (Department of Biology, University 
of Pennsylvania). 
Cell preparation. Liver and thymi obtained from fetuses of the 
appropriate age (day 12 through day 16 of gestation) were disaggre- 
gated in phosphate-buffered saline, pH 7.3 (PBS) using fine forceps 
and a single cell suspension obtained by repeated aspiration through 
a I-mL syringe barrel. BM mononuclear cells were obtained from 
the femurs and tibias of adult SCID mice by flushing the bones 
with PBS and repeated aspiration through a l-mL syringe barrel. 
Erythrocytes were removed by sedimentation centrifugation using a 
Ficoll Hypaque solution (FicoKite-LM, density 1.086g/mL; Atlanta 
Biologicals, Norcross, GA). Viable mononuclear cells were obtained 
from the interface, washed, and resuspended in  PBS containing 2% 
fetal calf serum (FCS; Atlanta Biologicals). Human peripheral blood 
mononuclear cells (PBMC) were obtained from whole blood donated 
by normal healthy adults after sedimentation centrifugation through 
Ficoll Hypaque solution (LSM, density 1.080 g/mL; Organon Tek- 
nika, Durham, NC). 
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Monoclonal antibodies (MoAbs). The following mouse and rat 
MoAbs were used to stain and analyze populations of cells isolated 
from the fetal liver, thymus, and adult BM by  flow cytometry: anti- 
mouse CD3UCD16IFcRyIYm (2.462, ATCC); CD12UIL2RP 
(TM-P1; gift from Dr Masayuki Miyasaka, Tokyo Metropolitan In- 
stitute of Medicine, Japan); CD45RIB220 (FL43-6B2; Pharmingen, 
San Diego, CA); Sca-l/LydA/E (E13-161.7; Pharmingen); CD901 
Thy 1.2 (30H.12; GIBCO-BRL, Gaithersburg, MD); CD24/HSA 
(M1/69; Pharmingen); Mac-l (Mlf70.15; Caltag Laboratories, San 
Francisco, CA); Gr-l (RE36-8C5; Pharmingen); CD43Ly-48 (S7; 
Pharmingen); IgM (Fab2 fragments goat-antimouse; Jackson Immu- 
noresearch, Westgrove, PA). Streptavidin-phycoeythrin and strepta- 
vidin-red 670  (SA-PE SA-RED670; GIBCO-BRL) were also used 
to detect reactivity of biotinylated primary antibodies. 
Flow cytometric analysis and cell sorting. All steps of the two- 
and three-color staining procedure were performed using 96-well, 
"V"-bottomed microtiter plates. Approximately 1 X lo5 cells in 50 
p L  of staining buffer (PBS, 2% FCS) were incubated with 5 pg of 
antimouse FcRy antibody for 1 hour at 4°C to block nonspecific 
binding of mouse and rat antibodies. The cells were then incubated 
with the appropriate biotin-conjugated antibodies for 45 minutes at 
4"C, washed twice, incubated for 30 minutes with SA-PE or SA- 
RED670, and flourochrome (FITC, Red 613, or PE)-conjugated anti- 
bodies and washed twice before flow cytometric analysis using a 
FACScan (Becton Dickinson, San Jose, CA). Antibody-positive pop- 
ulations of cells were distinguished according to the level of staining 
obtained with flourochrome-conjugated, mouse and/or rat Ig isotype- 
matched, control antibodies of irrelevant specificity. Ten thousand 
events were collected and analyzed using Lysis II software (Becton 
Dickinson). Because preliminary characterization of CD122+ cells 
in  the day 14 to 15 fetal liver indicated that a majority of  CD122' 
cells coexpressed FcRy IUIIII, they were in some instances first 
enriched for by positive immunomagnetic selection using the 2.4G2 
antibody before flow cytometric analysis and cell sorting. 
For cell sorting, 15 to 30 X lo6 fetal liver or SCID BM cells 
(BMC) were stained with anti-B220 and anti-CD24 antibodies as 
described above except the staining buffer contained antibiotics 
(PenicillidStreptomycin and Gentamycin; GIBCO-BRL). Stained 
cells were run on a FACStar Plus cell sorter (Becton Dickinson) 
and the  B220', and B220- fractions from fetal liver or B220fCD24- 
and B220+ CD24+ fractions from adult BM were collected in 2 to 
3 mL of media (DMEM with 10% FCS). 
Cellular proliferation assays. One to 5 X lo4 nonfractionated 
or sorted populations of fetal liver or adult SCID mouse BMC were 
cultured in 100 pL of DMEM/lO% FCS alone or in media containing 
100 ng/mL of recombinant murine IL-2 (Boehringer Mannheim, 
Indianapolis, IN) or recombinant human L 1 5  (Pepro Tech Inc. 
Rocky Hill, NJ) at 37°C for 48 hours. At this time, cultures were 
pulsed with 0.5 pCi of [3H] thymidine and cells were procured 12 
hours later. As a positive control for the effects of L - 2  on cellular 
proliferation, l@ freshly isolated human PBMC were cultured in 
RPM1 1640/5% FCS with 4 pg/mL PHA (Wellcome, Research Tri- 
angle Park, NC) for 48 hours, after which IL-2 or E-15 was added 
for a further 48 hours before pulsing with ['HI-thymidine as de- 
scribed for murine BMC cultures. 
Hybridization probes. All probes used for in situ hybridization 
were cDNA fragments consisting of sequences complementary to 
coding sequence only inserted into the polylinker site of the @EM- 
3 or -4 plasmids (Promega Corp, Madison, WI) using standard proce- 
dures. The L-2 and IL-2Ra (CD25) probes have been described 
Two nonoverlapping L - 2 w  probes corresponding 
to either the 176-729 or 9851,744-bp region of the gene" were 
used. The former cDNA clone was obtained from a day 15 mouse 
fetal thymus mRNA sample using a reverse transcriptase-polymerase 
chain reaction (RT-PCR) assay incorporating primers derived from 
the published sequence of the murine L-2RP gene sequence. The 
latter cDNA probe was kindly provided by Dr Glen Gaulton (Univer- 
sity of Pennsylvania). The identity of the cloned L-2RP cDNAs 
were confirmed by DNA sequencing. pGEM/cytokine/cytokine re- 
ceptor cDNA constructs were linearized and sense and antisense 35S- 
labeled RNA transcripts were synthesized using SP6 or T7 RNA 
polymerase according to the supplier's recommendations (Promega 
In situ hybridization. Cytocentrifuge preparations of fetal liver 
mononuclear cells were processed for hybridization in situ as de- 
scribed previo~sly.'~ Coded slides were hybridized with sense and 
antisense probes in triplicate and the number of silver grains overlay- 
ing samples hybridized with sense probes was  used  to determine the 
level of nonspecific hybridization (routinely between 1 and 5 grains 
per cell) and to identify mRNA+ cells in samples hybridized with 
antisense probes. From each coded slide, between 500 and 1,000 
positive cells from at least 10 different fields were examined to 
provide the frequency of positive cells per slide. For in situ hybrid- 
ization analysis of whole embryo sections, day 12 and day 13 mouse 
embryos were fixed in 4% (wt/vol) paraformaldehyde in PBS for 16 
to 20 hours at 20°C and stored in 70% ethanol until processed for 
paraffin-embedding and sectioning (American Histolabs, Gaithers- 
burg, MD). Six-micron sections were dewaxed in xylene, rehydrated 
in decreasing concentrations of ethanol, and then processed for hy- 
bridization in situ as described for cytocentrifuge samples. After 
hybridization (18 hours at 50°C) and posthybridization washes all 
of the samples were dipped in autoradiographic emulsion (NTB-2; 
Kodak, Rochester, NY) and developed after 1 to 4 days autoradiogra- 
phy at 4°C. Samples were counterstained with hematoxylideosin 
before mounting and photomicroscopy. 
Immunohistochemistry. Immunohistochemical staining of frozen 
 section^'^ of day 15 fetal liver and omentum was performed as 
described previo~sly.'~ The rat-antimouse IL-2  MoAB, S4B6, (Phar- 
mingen), 1 mg/mL, was used to detect IL-2 protein. Normal rat IgG 
(Miles Inc. Kankakee, L) was used as a control. As an additional 
specificity control the S4B6 antibody was preincubated with recom- 
binant IL2 (1,OOO U/mL) for 60 minutes at  20°C before staining. 
Corp). 
RESULTS 
Distribution of CD122 expression among murine fetal 
liver hematopoietic cells. Blood cell lineage-restricted 
stem cell populations are derived from a multipotential he- 
matopoietic stem cell (HSC) in the fetal liver and can be 
distinguished by the expression of lineage-specific surface 
antigens. HSC activity has been shown to be contained 
within a population of cells that expresses low levels of Thy- 
1, high levels of the stem cell-associated antigen, (Sca-1) 
and undetectable levels of blood cell lineage-specific differ- 
entiation markers (Lin)." To determine the stage in hemato- 
poiesis at which CD122 is first expressed, we analyzed cells 
from the day 12 fetal liver by three color flow cytometry 
using antibodies able to distinguish HSC and lineage-specific 
progenitor populations. The results shown in Fig  1 are repre- 
sentative of four independent experiments. The Sca-l+Lin- 
HSC population, represented approximately 2% of the mo- 
nonuclear cell fraction of day 12 C57BL.6 fetal liver cells 
(Fig 1C). Although CD122+ cells represented only 6% of 
the mononuclear fraction of the day 12 fetal liver (Fig lB), 
the Sca-l+Lin- population was enriched for cells expressing 
this cytokine receptor chain; approximately 20%  of the Sca- 
l+Lin- HSCs were CD122+ (Fig 1D). Interestingly, in 
subsequent analyses of CDl22-eMched fetal liver cell prep- 
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Fig 1. Expression of CD122 in 
the  fetal liver. Day 12 fetal liver 
mononuclear cells were  stained 
with either the anti-CD122 anti- 
body, TMpl (B) or an isotype- 
matched  antibody  of irrele- 
vant specificity (A). To identify 
CD122+ cella among  populations 
of  hematopoietic cells, samples 
of day 12 fetal liver cells were 
also stained with TW1,  Sca-1 
and lineages-specific (Lin) anti- 
bodies (Mac-l, Or-1, and 8220) 
then  anahzed  by three-color 
flow cytometry (C t o  E). The 
boxed  regions in (C) identify  the 
Sca-l+,  Lin- (4% of  total cells an- 
alyzed) and Lin' (6% of  total cells 
analyzed) populations analyzed 
for expression of CD122 (D and 
E, raspectivaly). The relative fre- 
quency of CDl22+ cells among 
dMerent fetal liver cell popula. 
8 .  tions  is  indicated  on each histo- 
CD122 gram. 
l!!!iL ,L
D E Sca-l+Lin- Lin+ 
e B 
arations (see Materials and Methods), expression of c-kit, a 
cell-surface antigen that distinguishes populations of pluripo- 
tential stem cells:' could not be detected (data not shown). 
Staining with  a combination of  F'ITC-labeled antibodies re- 
active with macrophages (Mac-l), granulocytes (Gr-l), B 
cells (B220) and erythroid cells (Ter 119) showed that be- 
tween 30% and 40% of lineage-committed cell populations 
(Scal', Lin+ and Sca-l-, Lin+) also expressed CD122 (Fig 
1E; discussed later). 
IL-2IUIL-2-mRNA and IL-2 protein expression in fetal 
hematopoietic tissues. Expression of CD122 in the day 12 
fetal liver was verified using in situ hybridization. Cytocen- 
trifuged fetal liver mononuclear cells were probed with anti- 
sense cDNA probes specific for CD122, developed, and the 
number of positive cells on each slide scored as described 
in Materials and Methods. As shown in Table 1, the propor- 
tion of CD122+ cells detected by in situ hybridization was 
similar to that observed by flow cytometry (4% to 6%). 
In addition, cells expressing mRNA encoding the a-chain 
(CD25) of the L-2-receptor were present at a similar fre- 
quency. Although we have been unable to detect surface 
liver (Fig 2, upper right panel). The ability to abolish reactiv- 
ity of the anti-IL-2 antibody by preincubating with an excess 
of recombinant IL-2 (upper left panel) shows the specificity 
of the staining. In addition, we also found abundant expres- 
sion of IL-2 in the day 15 fetal omentum (lower right panel, 
control shown on lower left), which is an active site of 
hematopoiesis during fetal development?'  In  both of these 
tissues it is interesting to note that L - 2  is not localized to 
specific cells or compartmentalized to defined areas of the 
tissue but has instead a rather diffuse and even distribution. 
Localization of IL-2 and IL-2RP-chain mRNA' cells in 
the day 12 embryo. To determine if CD122+ fetal liver 
cells were destined to colonize the thymus, we examined 
frozen sections of 5, day 12, C57BL.6 mouse embryos for 
expression of CD122 mRNA within areas of the developing 
neck and pharyngeal region adjacent to the developing thy- 
Table 1. % mRNA+ Cells in the Fetal Liver at Geatational Age 
d l 2  d l 4  
expression of CD25 on day 12 fetal liver cells, approximately Gene as.  S a s  S 
25%  of CD122+ cells in day 14 fetal liver coexpress IL2R IL-2Ra 4,2 (,20)+ <It 3.1 ( 2 2 0 )  
a (data not shown). These cytocentrifuge preparations were IL-PRfl 6.1 (10 2.7) 
< l  
< l  4.4 (11 rt 4.1) <l 
also analyzed for IL-2-mRNA expression. As shown in Table IL-2 4.5  (8.2 2 1.3)  <l 3.0 (>20)  < l  
a significant number Of L-2-mRNA+ were detected Cytocentrifuge preparations of cells probed  with 35S-labeled RNA 
in the liver at this time in gestation. probes synthesized in either the antisense (a.s) or sense (S) Orients- 
ence of IL-2 protein yielded results consistent with mRNA * Average grain count overlaying positive (>5 grains/cell) cells. 
expression. L - 2  protein was abundant in the day 15 fetal t Frequency of positive cells less than 10 in 1.000. 
"
Immunohistochemical staining of fetal tissues for the pres- tion. 
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Fig 2. Immunohistochemical localization of 1 1 2  
production in fetal hematopoietic tissues. Frozen 
sections  of day 15  C57BL.6 fetal liver (upper panels) 
and omentum  (lower panels) were stained with  the 
rat-antimouse IL-2 antibody, S4B6 (upper and lower 
right panels) or with antibody previously incubated 
with 1,000 UlmL of recombinant IL-2 (upper and 
lower left mnels). Bound antibodv was visualized 
_. .-. 
with a secondary biotinylated-antirat lg antibody 
and an avidin-biotin-peroxidase conjugate (ABC re- 
agent; Vector Labs). (Original magnification (OM) 
x40.) 
mus. Longitudinal sections from one of these embryos 
probed  with  "S-labeled  RNA probes complementary to ei- 
ther the coding or noncoding sequences of the &chain of 
the IL-2R  and  IL-2 showed an interesting pattern of  mRNA' 
cells (Fig 3). Individual cells expressing high levels of 
CD 122-mRNA' were detected in close proximity to the vas- 
cular endothelium of a branchial blood vessel directly above 
the developing pharynx (Fig 3A and upper panel A') and 
within the connective tissue immediately below it (Fig 3, 
lower panel A'). On adjacent sections of the same embryo, 
distinct clusters of cells expressing CD122-mRNA were also 
identified in association with the connective tissue below  the 
pharynx (Fig 3B) and adjacent to the developing pharyngeal 
pouches (Fig 3,  upper  and lower panels of B'). In addition, 
CD122-mRNA' cells were also localized to the base of the 
stem of the thymic analgen in the region of the third  pharyn- 
geal pouch (data not shown). A similar distribution of 
CD122-mRNA' cells was seen using additional embryo sec- 
tions processed in parallel or separately (Fig 3C). In contrast, 
no hybridization signal could be detected in any areas of 
adjacent embryo sections probed  with either a control, sense, 
IL-2RO (Fig 3D) or IL-2 (Fig 4B and B') probe. Interest- 
ingly, on sections of day 12 embryos probed with an anti- 
sense IL-2-specific probe, IL-2-mRNA' cells could be de- 
tected in close proximity to the developing thymus and 
within connective tissue surrounding the branchial arch (Fig 
4A and  A'). Consistent with findings from in  situ hybridiza- 
tion analysis of cytocentrifuge preparations (Table l), cells 
expressing the genes encoding the &chain of the IL-2R  and 
IL-2 were identified  within the liver of day 12 fetal embryo 
sections. 
The pattern of distribution of IL-2RP- and IL-2-positive 
cells within the pharyngeal region of day 12 embryos is 
consistent with their migration from the pharyngeal blood 
vessels after which they traverse the surrounding mesen- 
chyme before entering the This suggested that  at 
least some of the CD122' progenitor cells in the  pharyngeal 
region of the embryo sections may  be destined to enter the 
thymus and ultimately give rise to T cells. To directly ad- 
dress this possibility we analyzed thymocyte populations 
present within the day 13 fetal thymus for expression of 
CD122 using multicolor flow cytometry. 
CD122 is  expressed h? pre-T cell populations and is regu- 
lated during T-cell development. Although lymphoid cells 
are first detected in the mouse thymic rudiment  at  day 1 1  to 
12  of gestation, it is not until day 13 of mouse gestation that 
sufficient numbers of thymocytes can be isolated for flow 
cytometric analysis. In the day I3 thymus a small population 
of Sca-l+ cells (15%) can  be detected (Fig 5A). Analysis of 
CD122 expression revealed that more than 95% of these 
expressed CD122 (Fig 5B). In addition, this population of 
cells also expressed low levels of HSA (M169 antibody 
staining) and high levels of CD44 (data not shown). As 
thymocyte development progressed, the frequency of Scal ' 
cells (Fig 5C) and in particular Scal ' CD122' cells (Fig 
5D) declined, consistent with these cells being one of, if not 
the earliest thymic immigrant and T-cell precursor popula- 
tion.' 
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Expression of CD122 is regulated  during  B-cell develop- 
ment. In view  of our finding that a subset of  Lin' progeni- 
tor cells in the day 12 fetal liver express CD122 (Fig 1) we 
investigated the possibility that  B-cell progenitor populations 
(pro-B cells) may express this cytokine receptor chain. Using 
an antibody to B220, which is thought to represent the earli- 
est cell surface marker expressed by committed B cell pro- 
Fig 3. Localization of CD122- 
mRNA expressing cells in the 
neck region of a day 12 embryo. 
Six-micron paraffin-embedded 
sections of day 12 C57BL.6 
mouse  embryos  were  probed 
with 3sS-labeled RNA probes 
complementary to  mRNA encod- 
ing CD122 (A, B, and C) as de- 
scribed in Materials and Meth- 
ods.  As a control, a CD122 probe 
transcribed in  the sense orienta- 
tion  was also used (D). CD122- 
mRNA' cells present in (A) and 
(B) (arrowheads) are shown at 
higher  magnification in (A') and 
(B'), respectively. BV, branchial 
blood vessel; P, pharynx; PP, 
pharyngeal pouches, T, thymus. 
Magnification: (A), x200; (B) 
x250;  IC and D)  x320; A' and B', 
x 500. 
genitors,'.*' to analyze day 12 fetal liver cells it was deter- 
mined that (Fig 6C) the majority (>60%) of B220' cells 
were CD122'. The proportion of B220' cells that were 
CD122+ decreased during fetal life; whereas the proportion 
of B220' cells expressing CD122 was greater than  60%  at 
day 12 of gestation, only 10% of  B220' cells were CD122' 
in the day 15 fetal liver. Compared to B220+ cells, only a 
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Fig 4. Localization of IL-2-mRNA expressing cells in the neck region of a day 12 embryo. Six-micron paraffin-embedded sections of day 12 
C57BL.6 mouse  embryos  were  probed with either  an "S-labeled RNA probe  complementary to  mRNA encoding IL-2 (A and A') or as a control, 
an IL-2 probe  transcribed in the sense orientation (B and B') as described in Materials  and Methods. IL-2-mRNA' cells present in (A) are shown 
at  higher  magnification in (A'). B, branchial arch; PP, pharyngeal pouches; T, thymus. Magnification: (A and B') x320; (B) ~250;  (A') x500. 
dl3  Fetal Thvmus 
Fig 5. Expression of CD122 in the fetal thymus. 
Mononuclear cells isolated  from  the day 13 (A and 
B) and day 14 (C and Dl fetal  thymus  were  stained 
with anti-CD122, -Sca-l, and -CD45 antibodies  and 
analyzed by three-color flow cytometry. CD45'. Sca- 
1 b T-cell progenitor cells (A  and Cl were analyzed for 
expression of CD122 (B and D). The percentage of 
Sca-l'  or CD122' cells are indicated  on each histo- 
gram. The results are representative of three inde- 
pendent experiments. 
A CD45' B 
Sca-l 
dl4 Fetal Thymus 
c C D 4 S  D 
Sca- 1 
CD45'Sca-1' 
CD122 
CD45'Sca-l' 
I 
I 62%. 
<'l1122 
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CD122 B -d I *  l L . c ! J ! L  Is0 ctrl CD122 
d l 6  Fetal I.lver 
B2211 CD122 
Fig 6. Expression  of  CD122 during B-cell development in  the fetal liver. CD122  expression by developing B cells in the day 12 (A through 
C) and day 16 (D through F) fetal liver was analyzed by  three-color flow cytometry using antibodies specific for CD122,  8220. and CD24/HSA. 
The results are representative of those obtained from five independent experiments. In A through C, day  12 fetal liver  mononuclear  cells were 
stained with either an isotype control antibody (B) or the anti-CD122 antibody, TMpl (C). The boxed region in (A) identifies the 8220' CD122+ 
(2.4% of total cells analyzed) population shown as a histogram plot of  CD122'  cells in (C). Day 16 fetal liver  cells (D through F) were used to 
analyze CD122  expression  by pro-B cell  populations, as defined by the B220 and HSA antibody staining profile (D). The boxed regions in (D) 
identify the HSA' 8220' (upper box, representing 7% of cells analyzed) and the HSA- 8220' (lower box, representing 1%  of  cells analyzed) 
populations analyzed for  expression  of  CD122 (E and F, respectively). The frequency  of  CD122'  cells among B220+ HSA- (fraction A; E) and 
8220' HSA' (fraction B; F) pro-B  cell populations is shown on  each histogram. 
small proportion (between 10% and 20%) of developing 
erthyroid (TER 119') myeloid (Mac-l') and granulocytic 
(Gr-l') cells at this stage expressed CD122 (data not shown). 
To determine whether the expression of CD122 on  B220' 
day 12 fetal liver cells was restricted to a particular subset 
of B cells, we analyzed its expression on populations of day 
16 fetal liver cells using antibodies that have previously been 
used to resolve pro-B cells in the BM and fetal liver into 
three sequential stages (A through C) of development.'.*' 
Based  on the differential expression of the surface markers 
B220, CD24 (HSA), and BP-l, pro-B cells can  be  resolved 
into pre-pro-B (fraction A; B220'S7'HSA-), early pro-B 
(fraction B; B220+S7+HSAi"') and late pro-B (fraction C; 
B220'S7+HSAhi) populations. Since fraction A can be dis- 
tinguished from fractions B and C by the differential expres- 
sion of HSA, a three-color flow cytometric analysis using 
HSA- B220-  and CD 122-specific antibodies was performed. 
As  can  be  seen in Fig 6E, by day 16  of gestation the propor- 
tion of B220' pre-pro B cells (HSA-) that express CD122 
decreased to about 30% and of the newly emerging pro/ 
late pro-B cells (HSA') only 2% were CD122' (Fig 6F), 
consistent with its expression being restricted to an early B- 
cell precursor. These results were confirmed using BMC 
from SCID mice  that serve as an enriched source of pro-B 
cells (Fig 7A). As in the fetal liver, the B220' cells in SCID 
BM were fractionated into pre-pro B cells (B220'HSA-) 
and late pro B cells (B220'HSA') (Fig 7B).  The pattern  of 
expression of CD122 on these subpopulations was strikingly 
similar to that in fetal liver; approximately 80% of the 
B220'HSA- cells were CD122' (Fig 7C) whereas only 10% 
of B220'HSA' cells were CD122' (Fig 7D). 
Lymphoid progenitor cells proliferate preferentially to 
IL-2. To determine the functional significance of CD122 
expression by pro-B cell populations, cell fractions enriched 
for CD122 andor B220 expression were isolated from either 
day 15 fetal liver or BM of adult SCID mice using the 
fluorescence activated cell sorter and cultured in the presence 
of either IL-2 or IL-15. As can be seen in Fig 8 (which is 
representative of three different experiments), the B220' 
pro-B cell populations from both sources proliferated vigor- 
ously to IL-2. The analysis of SCID BMC response to IL-2 
shows that the responding cells within the HSA- fraction 
was further enriched for in the B220' fraction. This suggests 
that the ability to respond to IL-2 is primarily contained 
within this population of cells in the BM and fetal liver. 
Interestingly, although a small subset of  B220'HSA' pro-B 
cells in SCID BM are CD122', virtually no response to IL- 
2 could be detected. The difference in the response of the 
B220'HSA- cells obtained from the adult BM (stimulation 
index 1 0 0  to 125) and the fetal liver B220'  (S.I. 3 to 4) cells 
probably reflects the difference in frequency of CD1 22' cells 
in each sample. Among the B220' cells isolated from day 
15 fetal liver the CD122' population represented less than 
10% whereas in the adult BM samples 80% of the B220' 
HSA- expressed CD122'. This increase in the size of the 
B220TD122' cell pool in the SCID BM  may simply reflect 
the expansion of these cells in the absence of more mature 
B-cell populations. It  is also possible that it  may  be a conse- 
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Fig 7. Expression  of CD122 on B220+ cells in  the 
BM of adult SClD mice. Populations of developing B 9 
cells were identified using combinations of antibod- = 
ies  specific  for 8220, CD24lHSA. and CD43/S7 (A and 
B )  and analyzed for  expression of CD122 by two- f 
and  three-color flow cytometry (C and D). The boxed 
areas shown in (B) were used to identify and analyze 3 
pre-pro B (fraction B; lower box) and pro/late pro B 
(fraction C; upper box) cells  for  expression  of CD122 
(C and D, respectively). The relative proportion of 
each  pro-B  cell population that is CD122' is shown 
on  each  of the histograms. 
c B220+HSA(Pre-h B cells) D BZZO+HSA+(h/late Pro B cells) 
quence of differences in the hematopoietic microenviron- 
ments present within the fetal liver and BM. These microen- 
vironments may also change over time in such a way that 
they are only able to support the expansion and development 
of different progenitor populations during distinct periods of 
an animal's development. The decline in the proportion of 
B220' fetal liver cells that are CD122' between day 12 and 
15 of gestation may  be a consequence of such a phenomenon. 
The specificity of the B220'CD122' cells response to cyto- 
kines was shown by the absence of any proliferative response 
to IL-15. The optimal concentration of IL-2 (100 ng/mL) 
and IL-15 (100 ng/mL) for proliferation was determined by 
incubating PHA-stimulated human peripheral blood lympho- 
cytes with varying concentrations of  IL-2 or IL-15 (data not 
shown). In addition, we have also consistently failed to show 
any proliferative response to IL-15 over a wide range of 
concentrations in total or fractionated day 12 to 16 fetal liver 
cell populations (data not shown). 
A loss of B220' cells in  the  bone marrow of IL-2-dejcient 
mice. The observation that large amounts of IL-2 protein 
are present in the fetal liver (Fig 2) and that  B220'CD122' 
cells in the fetal liver and adult BM proliferate in response 
to IL-2, suggests that  they  may utilize this cytokine in some 
way during their development in vivo. Consequently, we 
examined IL-2-deficient mice for evidence of  any disruption 
of B-cell generation. As previously reported, up to 2 weeks 
of age the B-cell composition of the IL-2-/- mice was very 
similar to that of wild type (IL-2"') mice?" However, be- 
yond 2 weeks of age a progressive loss B220+ cells was 
seen in IL-2"- until by approximately 6 weeks of age the 
B220' cells represented only 6% of the mononuclear cell 
14% 
LX" CD1 22 'L 
fraction in the BM (Fig 9). Populations of immature (pro-, 
pre-) and mature (IgM') B cells (B220+) were equally af- 
fected (T.R. and  S.R.C., manuscript submitted). Considering 
the number of cells recovered from the femurs of  IL-2"- (6 
X 10") and IL-2+/+  (1 1 X 10") shown in Fig 9 this reduction 
in frequency of  B220' cells represents a more than sixfold 
reduction in the absolute number of B cells in the IL-2"- 
mice. Similar results have been obtained from the analysis 
of an additional 20 IL-2"- mice. 
DISCUSSION 
The expression of CD122 (the IL-2/IL-l5R @-chain) by 
developing hematopoietic cell populations during the fetal 
and adult phases of hematopoiesis in C57BL.6 mice has been 
characterized. We have shown that CD122 is expressed by 
multiple hematopoietic cell populations and in particular by 
T- and  B-cell progenitors. In embryo sections, cells express- 
ing this receptor were identified in and around the thymus 
during progenitor cell colonization and the majority of cells 
of the earliest pro-T cell population (expressing Scal) also 
were found to express CD122. During B-cell development, 
expression of this cytokine receptor is also tightly regulated, 
being almost entirely restricted to the earliest known  B-cell 
progenitor population, the pre-pro or fraction A' B cells. 
Moreover, we have shown that during lymphoid cell devel- 
opment in the fetal liver, large amounts of IL-2 are produced 
in situ at the time CD122' progenitor populations are pres- 
ent. The significance of this observation was reinforced by 
our finding that highly purified adult BM and fetal liver 
CD122' fraction A pro-B cells proliferate in response to IL- 
2 but  not to IL-15. Interestingly, the ability of these cells to 
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respond  to L-2 was  independent  of  any  stromal  cell  contact. 
Finally, we  have  shown  that  in L-2-deficient mice  there  is 
a  progressive  loss of  B220' cells in  the  BM,  consistent  with 
a  requirement  for  IL-2  for  the  continued  generation  andlor 
viability of developing  B  cells. 
The  frequency of CD122+  cells (6% to 7%) in  the  mouse 
fetal liver contrasts with the much higher frequency of 
CD122  mRNA' cells  (approximately 75%) identified  in  the 
human fetal liver.27 Although the authors of this study in- 
ferred  the  presence of P-chain-containing L-2R on  the  basis 
of showing the expression of intermediate-affinity L 2 R ,  
Fig 9. B220 expression in the BM of IL-2-deficient  mice. Mononu- 
clear BMC from &week-old IL-2-deficient (-/-l and age-matched 
wild-type littermate control (+/+l mice  were stained with B22O-FlTC 
and  analyzed by flow cytometry. The  percentage of cells that were 
positive for B220 is indicated on  the histograms. 
REYA ET AL 
Fig 8. 112-induced expansion of W O +  cells from 
fetal liver and adult BM.  Populations  of M A + ,  HSA-, 
B220* and/or 8220-  cells  were isolated from the day 
12 fetal liver or  BM  of aduk SCID mice by FACS and 
cultured in media  alone  or in media containing 100 
ng/mL of 11-2 or 11-15 for 48 hours.  Relative  amounts 
of 3H-thymidine incorporation for each of the cell 
populations analyzed is shown in  the insets of each 
figure. The ratio of  cpm obtained from cells cultured 
in the absence  and  presence  of  IL-2 or IL-15  was  used 
to determine the stimulation index. 
using '251-labeled L-2, it was not possible to enumerate 
the  cells  expressing  surface L-2R-p chains.  Therefore,  it  is 
possible  that  CD122-mRNA  detected  might  not be translated 
and  expressed  on  the  surface  of  the  mRNA+ cells.  Alterna- 
tively,  the  difference  in  frequency of  CD 122+  cells reported 
in these studies could reflect differences in the regulation 
and/or  cellular  distribution of this  cytokine  receptor  chain 
during  hematopoiesis  in  humans  and  mice. 
From our detailed  analysis of the  distribution of CD122 
on  various  hematopoietic  subpopulations in the  day  12  fetal 
liver we have identified CD122 expression on a subset of 
1 
+/+ I -/L 
B220 
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Sca-l+Lin- hematopoietic stem cells. However, because this 
fetal liver population does not express c-kit (data not shown), 
an antigen that has previously been shown to be expressed 
at high levels by pluripotential stem cells,2‘ it is possible 
that CD122 expression is restricted to lineage-committed 
progenitor populations. The expression of CD122 by cells 
committed to either the myeloid (Mac-l+), granulocytic (Gr- 
l+), or erythroid (Ter 119’; data not shown) progenitors is 
consistent with this interpretation. The lack of c-kit expres- 
sion by B220+CD122+ fetal liver cells would appear, on the 
basis of previous phenotypic characterization of lymphocyte 
progenitor populations which have shown them to be c- 
to exclude it from being a pro-B population. How- 
ever, there are several possible explanations for this inconsis- 
tency. A trivial explanation is that since we have used the 
anti-FcRyIVIII antibody, 2.4G2, to enrich for CD122+ cells 
from the fetal liver it is possible that a B220+FcRy II/III-c- 
kit+CD122+ progenitor population may also be present but 
was excluded from our analyses. Alternatively, it is possible 
that CD122 expression during B-cell development in the 
fetal liver is primarily restricted to a pre pro-B cell popula- 
tion that precedes the c-kit+ pro-B cell stage; the population 
we have described may acquire c-kit expression as they de- 
velop. Although we have not characterized c-kit expression 
on CD122-mRNA+ cells that are found in close association 
with the day 12 thymus, if they are (Fig 3 and below) c- 
kit-, it may indicate that this antigen is acquired during 
their development upon entry into the thymus. Furthermore, 
during colonization, the thymus may be seeded by both c- 
kit- and c-kit+ progenitor cell populations. Finally, in view 
of the demonstration that fetal liver- and adult BM-derived 
T-cell progenitor populations can be distinguished by their 
maturational potential,” it is possible that the phenotype of 
progenitor cells that colonize the thymus during fetal and 
adult life may also be different in that adult progenitors may 
express c-kit whereas fetal progenitors may not. 
Previous studies have shown that during colonization, 
blood-borne pro-T cells leave adjacent vessels and traverse 
the surrounding mesenchyme before seeding the t h y m ~ s . ~ ~ , ~ ~  
The presence of CD122 mRNA+ cells within the pharyngeal 
blood vessels and in close proximity to the developing thy- 
mus is consistent with them being in the process of migrating 
to the thymus and suggests that T-cell precursors migrating 
from the liver to the thymus express CD122. In agreement 
with this idea is our observation that the majority of Seal+ 
intrathymic T-cell precursors within the day 13 thymus are 
CD122+ and the demonstration by Falk et a18 that this popu- 
lation of cells isolated from day 14 fetal thymi can give rise 
to functionally mature T cells. Although the nature of the 
mechanism@) involved in promoting or regulating stem cell 
migration and thymic colonization are not known, some stud- 
ies have implied the involvement of specific homing mole- 
cules” and thymic-chemotactic  factor^.'^ The co-localization 
of IL2-mRNA+ cells in close proximity to the developing 
thymus in adjacent day 12 embryo sections suggests that IL- 
2 (or another cytokine able to interact with CD122) may 
also facilitate stem cell migration perhaps by maintaining 
their viability during transit. 
From our analysis of B-cell development in the fetal liver 
and adult BM insights into the role CD122 may play in 
lymphopoiesis have been obtained. In both the day 12 fetal 
liver and adult SCID BM CD122 expression on B-lineage 
cells was developmentally regulated, being restricted to the 
earliest defined B-cell progenitor population, the pre-pro B 
cells that are B220’HSA- (fraction A). Our finding that pre- 
pro B cells can be divided into CD122+ and CD122- subsets 
implies, as originally proposed by Hardy et al? that this 
population is phenotypically heterogeneous. The observation 
that large numbers (lo5) of fraction A cells are required to 
reconstitute B cells in irradiated SCID recipients also implies 
that these cells are functionally heterogeneous. However, 
this result together with the finding that highly purified prep- 
arations of fraction A cells can give rise to pro-B cells (frac- 
tion B and C) after short term culture in vitro with stromal 
cells shows that this population of cells contains B-cell pro- 
genitors. At this time we do not know if this progenitor 
activity is contained within the CD122+ or CD122- subset. 
Because several studies have shown that the B220-isoform 
of CD45 can also be expressed by mitogen- and cytokine- 
activated T cells:’ activated-natural killer (NK) cells3’ and 
other lymphokine-activated major histocompatibility com- 
plex-nonrestricted killer (LAK) cells” it is possible that the 
CD122+B220+HSA- cells we have detected in the fetal liver 
may contain cells not only of the B lineage but of other 
lineages as well. In  view of the observation that CD122 is 
constitutively expressed by developing murine splenic NK 
cells3’ it is possible that the B220+CD122+ fetal liver and 
BM population may be multipotential. However, because 
our studies have been performed at a time in gestation before 
the generation of functionally mature T cells and because 
CD122+ NK1.1+ cells can only be detected after birth3’ it is 
likely that the CD122+B220+ cells we have identified in the 
day 12 fetal liver are primarily B-cell progenitors. 
As cells progressed through subsequent stages of B-cell 
development CD122 expression was downmodulated with 
pre-B cells (fraction C) being essentially devoid of any 
CD122 expression. This developmentally regulated expres- 
sion of CD122 is particularly interesting in light of recent 
results showing that among developing B-cell populations 
in the adult BM the IL-2Ra-chain (CD25) is restricted to 
pre-B cells.536 Although  we have identified a population of 
CD122+ cells that express CD25 in the day 14 fetal liver 
(data not shown) it is possible that these cells are B220-. 
Although the ability of C D 2 9  pre-B cells to respond to IL- 
2 was not directly tested, the results from previous studies 
showing that in the absence of the p- and y-chains the a- 
chain is incapable of mediating signals in response to IL-2 
suggest that CD122+ pre-pro B cells can be distinguished 
from CD25+ pre-B cells by  their ability to respond to IL-2 
in vitro. 
Perhaps the most interesting feature of the proliferative 
response of the B220+HSA-CD122+ cells to IL-2 is that it 
occurred in the absence of any stromal cell contact. Although 
this contrasts with the inability of other known B-cell growth 
factors (eg, IL-7 and steel locus factor) to promote the expan- 
sion of pro-B cells in the absence of stromal it 
is similar to the IL-7-induced, stromal cell independent, 
proliferation of BM-derived pre-B Together these 
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results suggest that different cytokines function in conjunc- 
tion  with, or independently of, stromal cells in a stage-spe- 
cific manner to regulate the growth and differentiation of 
developing B cells. 
The presence of IL-2 protein in the fetal liver at the time 
when CD122+ pro-B cells can be detected suggests that these 
cells may normally use IL-2 in vivo. A possible source of 
this IL-2 are 76 T cells that  we have previously identified38 
in the day 12 fetal liver of C57BL.6 mice. However, the 
production of IL-2 from a non T-cell source is also possible. 
Indeed, morphologic analysis of the IL-2-mRNA+ cells sug- 
gest that some may be of the myelo-granulocytic lineage. 
Further experimentation is required to definitively identify 
the cellular source of this IL-2-mRNA. Our  finding  that IL- 
2 was produced by cells in the fetal omentum is interesting 
because besides being  an embryonic source of T and B lym- 
phocytes in the mousez2 it is also the principal tissue from 
which  CD5'" B cells arise." These B cells represent a sepa- 
rate lineage that can be distinguished from conventional B 
cells with  regard to several  characteristic^.^^-" Fetal omen- 
tum has also been shown to give rise to IgA producing cells 
in  the Therefore, we cannot exclude the possibility 
that some B-cell populations may express and/or use IL-2 
during their development. 
Although it was originally reported that lymphocyte devel- 
opment was normal in IL-2-deficient mice26 our finding  that 
these animals have dramatically reduced numbers of B cells 
by 6 weeks of age clearly shows that B-cell generation, 
expansion and/or viability is severely compromised. Al- 
though  we do not  yet have an explanation for why this defect 
is not apparent earlier in these mice, it  may  reflect differences 
in the requirement for IL-2 by lymphocyte progenitor popu- 
lations that arise at different times during the lifespan of the 
animal (eg, fetal, neonatal, and adult stages). Alternatively, 
IL-2 through its mitotic activity may serve to maintain the 
viability and the size of CD122'B220+ cells in  vivo as sug- 
gested by our observation that this population proliferates in 
response to this cytokine (Fig 7). Therefore, in the absence 
of an endogenous or exogenous supply of IL-2  this progeni- 
tor pool may eventually become exhausted as a consequence 
of the successive waves of B-cell development that occur 
before and after birth, eventually producing the phenotype 
we observe in the IL-2-deficient mice after 6 weeks of age. 
Interestingly, we have also identified a similar late-onset 
defect in other hematopoietic cell populations in these mice 
(T.R. and S.R.C., manuscript submitted). Very recently a 
similar late-onset defect in B-cell generation and/or viability 
has been observed in CD122-deficient mice!' Although the 
authors of this study suggest that this may be caused by the 
presence of large numbers of activated CD4' T cells, the 
possibility that B-cell progenitor activity was also affected 
was not addressed. However, the observation that B-cell 
colony formation was significantly reduced in these mice 
even at 1 week of age, at which time the spleen contains 
very few T cells, implies that there may be an intrinsic B- 
cell defect in these mice. These mice also displayed abnor- 
mal levels of granulocyte and erythrocyte production, which 
in  view  of our finding that CD122 is expressed by immature 
granulocytic and erythroid cells in the fetal liver may  reflect 
a requirement for IL-2 during their development in vivo. 
In summary, all our results are consistent with a role for 
the IL-2-IL-2R signaling pathway in lymphocyte develop- 
ment perhaps by regulating the size of the progenitor pool 
or by promoting their progression through different develop- 
mental stages. 
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